Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing neurological therapeutics, has received an extension from NYSE Regulation to regain compliance with NYSE American continued listing standards. The extension, granted through February 25, 2028, follows the acceptance of the company's compliance plan and allows Oragenics to maintain its exchange listing while implementing measures intended to strengthen its financial position, subject to meeting plan milestones and ongoing review requirements.
The company initially received a noncompliance notice on August 26, 2026, after reporting stockholders' equity of $3.7 million as of June 30, 2026, and losses from continuing operations and/or net losses in its five most recent fiscal years. Oragenics submitted its compliance plan on September 25, 2026, and received formal acceptance on November 11. The extension provides the company with additional time to address these deficiencies and pursue its strategic priorities.
CEO Janet Huffman said the extension will allow Oragenics to continue pursuing its strategic priorities, capital-raising initiatives, and investment strategies aimed at enhancing long-term shareholder value. The approval is significant for the company as it seeks to advance its lead candidate, ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The company's proprietary intranasal delivery technology is designed to target the brain directly and has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
Maintaining the NYSE American listing is crucial for Oragenics, as it provides access to capital markets and visibility among investors. The extension offers a runway for the company to execute its business plan and potentially achieve milestones that could drive value. For the biotechnology industry, this development underscores the challenges clinical-stage companies face in meeting exchange listing standards while funding costly research and development. It also highlights the importance of compliance plans in providing a pathway for companies to address financial deficiencies without immediate delisting.
Investors and industry observers can follow Oragenics' progress through its newsroom at https://ibn.fm/OGEN. The full press release is available at https://ibn.fm/LiPlM. More information about the company can be found at oragenics.com.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform offers editorial syndication to 5,000+ outlets and social media distribution to reach a broad audience. For more details, visit https://www.BioMedWire.com and review the disclaimer.
